Capital International’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $94.8M | Buy |
506,085
+33,774
| +7% | +$6.35M | 3.1% | 6 |
|
|
2026
Q1 | $92.3M | Buy |
+472,311
| New | +$91.1M | 3.42% | 6 |
|
|
2024
Q4 | – | Sell |
-19,620
| Closed | -$3.06M | – | 146 |
|
|
2024
Q3 | $3.06M | Buy |
19,620
+142
| +0.7% | +$22.9K | 0.13% | 123 |
|
|
2024
Q2 | $3.04M | Sell |
19,478
-2,332
| -11% | -$351K | 0.14% | 122 |
|
|
2024
Q1 | $2.96M | Buy |
21,810
+379
| +2% | +$50.2K | 0.14% | 125 |
|
|
2023
Q4 | $2.89M | Sell |
21,431
-1,531
| -7% | -$199K | 0.15% | 127 |
|
|
2023
Q3 | $3.11M | Sell |
22,962
-145
| -0.6% | -$19.8K | 0.18% | 120 |
|
|
2023
Q2 | $3.31M | Hold |
23,107
| – | – | 0.19% | 118 |
|
|
2023
Q1 | $3.21M | Buy |
23,107
+1,506
| +7% | +$203K | 0.19% | 123 |
|
|
2022
Q4 | $2.93M | Buy |
21,601
+5,909
| +38% | +$741K | 0.2% | 121 |
|
|
2022
Q3 | $1.72M | Buy |
15,692
+7,945
| +103% | +$1.01M | 0.12% | 140 |
|
|
2022
Q2 | $1.02M | Buy |
+7,747
| New | +$1.02M | 0.08% | 143 |
|
|
2020
Q3 | – | Sell |
-8,873
| Closed | -$939K | – | 155 |
|
|
2020
Q2 | $939K | Sell |
8,873
-27,200
| -75% | -$2.81M | 0.09% | 136 |
|
|
2020
Q1 | $3.22M | Sell |
36,073
-10,877
| -23% | -$1.02M | 0.36% | 70 |
|
|
2019
Q4 | $4.68M | Sell |
46,950
-600
| -1% | -$56.5K | 0.49% | 61 |
|
|
2019
Q3 | $4.24M | Hold |
47,550
| – | – | 0.64% | 49 |
|
|
2019
Q2 | $3.93M | Sell |
47,550
-2,400
| -5% | -$188K | 0.93% | 28 |
|
|
2019
Q1 | $4.04M | Buy |
49,950
+1,450
| +3% | +$114K | 0.97% | 29 |
|
|
2018
Q4 | $3.68M | Buy |
48,500
+18,900
| +64% | +$1.48M | 1% | 29 |
|
|
2018
Q3 | $2.34M | Hold |
29,600
| – | – | 0.73% | 36 |
|
|
2018
Q2 | $2.08M | Sell |
29,600
-850
| -3% | -$61.2K | 0.36% | 82 |
|
|
2018
Q1 | $2.13M | Sell |
30,450
-600
| -2% | -$41.6K | 0.38% | 77 |
|
|
2017
Q4 | $2.15M | Hold |
31,050
| – | – | 0.41% | 75 |
|
|
2017
Q3 | $2.1M | Hold |
31,050
| – | – | 0.14% | 89 |
|
|
2017
Q2 | $2.12M | Hold |
31,050
| – | – | 0.14% | 92 |
|
|
2017
Q1 | $1.93M | Hold |
31,050
| – | – | 0.13% | 92 |
|
|
2016
Q4 | $1.7M | Hold |
31,050
| – | – | 0.12% | 99 |
|
|
2016
Q3 | $2.04M | Hold |
31,050
| – | – | 0.14% | 96 |
|
|
2016
Q2 | $1.88M | Sell |
31,050
-9,150
| -23% | -$531K | 0.14% | 101 |
|
|
2016
Q1 | $2.26M | Hold |
40,200
| – | – | 0.15% | 105 |
|
|
2015
Q4 | $2.73M | Hold |
40,200
| – | – | 0.17% | 103 |
|
|
2015
Q3 | $2.56M | Buy |
40,200
+22,300
| +125% | +$1.47M | 0.17% | 100 |
|
|
2015
Q2 | $1.14M | Sell |
17,900
-700
| -4% | -$47.9K | 0.07% | 135 |
|
|
2015
Q1 | $1.27M | Buy |
+18,600
| New | +$1.29M | 0.08% | 120 |
|
Other funds holding AZN
EP
IA
Capital International's AZN Position: Q2 2026 in Review
Capital International increased its AstraZeneca (AZN) stake by 7.2% in Q2 2026, buying an estimated $6.35M and bringing the position to 506,085 shares worth $94.8M. The position accounts for 3.1% of the portfolio, ranked #6.
Capital International first reported a position in AZN in Q1 2015 and has held it in 34 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Capital International held 506,085 shares of AstraZeneca worth $94.8M as of Q2 2026.
- Capital International bought 33,774 AstraZeneca shares in Q2 2026, an estimated $6.35M.
- AstraZeneca made up 3.1% of Capital International's portfolio in Q2 2026, its #6 holding.
- Capital International first reported a position in AstraZeneca in Q1 2015 and has held it in 34 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Capital International's 13F filing for Q2 2026, filed 12 Aug 2026.